Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Bevacizumab
Disease-Free Survival
Disease-Free Survival
Double-Blind Method
Double-Blind Method
Female
Female
Gastrointestinal Diseases
Gastrointestinal Diseases
Humans
Humans
Logistic Models
Logistic Models
Middle Aged
Middle Aged
Neoplasm Staging
Neoplasm Staging
Organoplatinum Compounds
Organoplatinum Compounds
Ovarian Neoplasms
Ovarian Neoplasms
Risk Factors
Risk Factors
Taxoids
Taxoids
Young Adult
Young Adult
authors with profiles
Joan L Walker